Compare Dr. Reddys with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs DISHMAN PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB DISHMAN PHARMA DR. REDDYS LAB/
DISHMAN PHARMA
 
P/E (TTM) x 40.2 25.1 160.0% View Chart
P/BV x 5.4 3.3 162.2% View Chart
Dividend Yield % 0.4 0.7 65.5%  

Financials

 DR. REDDYS LAB   DISHMAN PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
DISHMAN PHARMA
Mar-16
DR. REDDYS LAB/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,875374 767.9%   
Low Rs1,888129 1,464.7%   
Sales per share (Unadj.) Rs930.2197.8 470.3%  
Earnings per share (Unadj.) Rs117.421.2 553.7%  
Cash flow per share (Unadj.) Rs185.834.7 535.0%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.80.8 105.7%  
Book value per share (Unadj.) Rs844.4179.9 469.4%  
Shares outstanding (eoy) m166.0780.69 205.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.61.3 201.2%   
Avg P/E ratio x20.311.9 170.9%  
P/CF ratio (eoy) x12.87.2 176.9%  
Price / Book Value ratio x2.81.4 201.6%  
Dividend payout %17.09.4 180.6%   
Avg Mkt Cap Rs m395,49620,306 1,947.7%   
No. of employees `00022.00.8 2,649.7%   
Total wages/salary Rs m33,5625,355 626.8%   
Avg. sales/employee Rs Th7,032.819,252.7 36.5%   
Avg. wages/employee Rs Th1,527.96,459.5 23.7%   
Avg. net profit/employee Rs Th887.72,064.1 43.0%   
INCOME DATA
Net Sales Rs m154,48215,961 967.9%  
Other income Rs m3,375265 1,271.7%   
Total revenues Rs m157,85716,226 972.9%   
Gross profit Rs m31,7824,103 774.6%  
Depreciation Rs m11,3481,091 1,040.5%   
Interest Rs m889944 94.1%   
Profit before tax Rs m22,9202,334 982.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m4381 39,818.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858624 618.7%   
Profit after tax Rs m19,5001,711 1,139.6%  
Gross profit margin %20.625.7 80.0%  
Effective tax rate %16.826.7 63.0%   
Net profit margin %12.610.7 117.7%  
BALANCE SHEET DATA
Current assets Rs m111,10111,018 1,008.4%   
Current liabilities Rs m58,9739,517 619.7%   
Net working cap to sales %33.79.4 358.8%  
Current ratio x1.91.2 162.7%  
Inventory Days Days79110 71.8%  
Debtors Days Days9435 270.4%  
Net fixed assets Rs m101,24516,304 621.0%   
Share capital Rs m830161 514.3%   
"Free" reserves Rs m139,40612,907 1,080.1%   
Net worth Rs m140,23614,516 966.1%   
Long term debt Rs m22,0004,189 525.1%   
Total assets Rs m224,65629,805 753.8%  
Interest coverage x26.83.5 771.6%   
Debt to equity ratio x0.20.3 54.4%  
Sales to assets ratio x0.70.5 128.4%   
Return on assets %9.18.9 101.9%  
Return on equity %13.911.8 118.0%  
Return on capital %14.917.5 85.3%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m88,6734,952 1,790.8%   
Fx outflow Rs m19,104697 2,741.7%   
Net fx Rs m69,5694,255 1,635.1%   
CASH FLOW
From Operations Rs m28,7042,786 1,030.1%  
From Investments Rs m-7,727-1,529 505.4%  
From Financial Activity Rs m-21,326-941 2,266.1%  
Net Cashflow Rs m-314316 -99.2%  

Share Holding

Indian Promoters % 25.5 61.4 41.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 3.7 145.9%  
FIIs % 35.3 12.7 278.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 22.1 69.2%  
Shareholders   75,885 46,261 164.0%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 225 Points Higher; Metal and Banking Stocks Witness Buying(Closing)

Extending gains to the fourth consecutive session, Indian share markets witnessed buying interest throughout the day today and ended higher.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 11, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS